Andra AP fonden Buys More Merck & Co., Inc. Stock Amid Analyst Optimism
Merck & Co., Inc.'s (NYSE:MRK) stock saw significant interest from institutional investors in the second quarter. Andra AP fonden, a fund, increased its stake in MRK by 6.8% during the period. The company's EVP David Maraldo and EVP Jennifer Zachary sold shares of their own stock recently.
According to regulatory filings, Andra AP fonden purchased an additional 24,800 shares of MRK during the second quarter, bringing its total holdings in the company to 389,285 shares worth $50.023 million at the end of the reporting period. This is part of a broader trend of institutional investors increasing their exposure to MRK.
The pharmaceutical giant has seen its stock price fluctuate recently due to various factors including new product approvals and earnings releases. On August 4th, Merck & Co., Inc. reported a net margin of 4.77% and a return on equity of 16.73%. The company's quarterly revenue was up 5.1% year-over-year.
Despite these fluctuations, analysts remain optimistic about MRK's growth prospects. Several brokerages have boosted their target prices for the stock, with Wolfe Research increasing its target to $180 from $155 and UBS Group raising its price objective to $175 from $145.